Related Experiment Video
Updated: Apr 15, 2026

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
Subvisible (2-100 μm) Particle Analysis During Biotherapeutic Drug Product Development: Part 1, Considerations and
Linda O Narhi1, Vincent Corvari2, Dean C Ripple3
1Amgen, Process Development, Thousand Oaks, California.
Abstract:
Measurement and characterization of subvisible particles (defined here as those ranging in size from 2 to 100 μm), including proteinaceous and nonproteinaceous particles, is an important part of every stage of protein therapeutic development. The tools used and the ways in which the information generated is applied depends on the particular product development stage, the amount of material, and the time available for the analysis. In order to compare results across laboratories and products, it is important to harmonize nomenclature, experimental protocols, data analysis, and interpretation. In this manuscript on perspectives on subvisible particles in protein therapeutic drug products, we focus on the tools available for detection, characterization, and quantification of these species and the strategy around their application.
More Related Videos
08:31Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
Published on: December 1, 2020
18:46Methods Development for Blood Borne Macrophage Carriage of Nanoformulated Antiretroviral Drugs
Published on: December 9, 2010
Related Concept Videos
Factors Affecting Dissolution: Particle Size and Effective Surface Area
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Clinically Relevant Drug Product Specifications: Methods of Establishment
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Bioavailability Enhancement: Drug Solubility Enhancement
Factors Influencing Drug Absorption: Drug Dissolution